Keros Therapeutics Stock Net Income
| KROS Stock | USD 14.32 0.15 1.04% |
Fundamental analysis of Keros Therapeutics allows traders to better anticipate movements in Keros Therapeutics' stock price by examining its financial health and performance throughout various phases of its business cycle.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Keros Therapeutics Company Net Income Analysis
Keros Therapeutics' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Keros Therapeutics Net Income | (187.35 M) |
Most of Keros Therapeutics' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Keros Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Keros Therapeutics reported net income of (187.35 Million). This is 154.9% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 132.81% higher than that of the company.
Keros Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Keros Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Keros Therapeutics could also be used in its relative valuation, which is a method of valuing Keros Therapeutics by comparing valuation metrics of similar companies.Keros Therapeutics is currently under evaluation in net income category among its peers.
Keros Fundamentals
| Return On Equity | 0.0071 | ||||
| Return On Asset | -0.0101 | ||||
| Profit Margin | 0.02 % | ||||
| Operating Margin | 0.72 % | ||||
| Current Valuation | (120.11 M) | ||||
| Shares Outstanding | 40.62 M | ||||
| Shares Owned By Insiders | 2.30 % | ||||
| Shares Owned By Institutions | 97.70 % | ||||
| Number Of Shares Shorted | 5.05 M | ||||
| Price To Book | 0.80 X | ||||
| Price To Sales | 2.71 X | ||||
| Revenue | 3.55 M | ||||
| Gross Profit | 204.26 M | ||||
| EBITDA | (185.82 M) | ||||
| Net Income | (187.35 M) | ||||
| Cash And Equivalents | 215.62 M | ||||
| Cash Per Share | 8.37 X | ||||
| Total Debt | 18.86 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 14.39 X | ||||
| Book Value Per Share | 17.97 X | ||||
| Cash Flow From Operations | (160.87 M) | ||||
| Short Ratio | 10.63 X | ||||
| Earnings Per Share | (0.17) X | ||||
| Target Price | 24.0 | ||||
| Number Of Employees | 163 | ||||
| Beta | 1.26 | ||||
| Market Capitalization | 581.61 M | ||||
| Total Asset | 615.89 M | ||||
| Retained Earnings | (568.78 M) | ||||
| Working Capital | 561.44 M | ||||
| Current Asset | 11.95 M | ||||
| Current Liabilities | 5.72 M | ||||
| Net Asset | 615.89 M |
About Keros Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Keros Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Keros Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Keros Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Keros Stock Analysis
When running Keros Therapeutics' price analysis, check to measure Keros Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Keros Therapeutics is operating at the current time. Most of Keros Therapeutics' value examination focuses on studying past and present price action to predict the probability of Keros Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Keros Therapeutics' price. Additionally, you may evaluate how the addition of Keros Therapeutics to your portfolios can decrease your overall portfolio volatility.